ARCHIVES

Study Tests PARP Inhibitor ABT-888 For Several Cancers

This article is from The Cancer Letter archive.

Vol. 32 No. 9 | September 25, 2009

Download PDF Visit The Full Archive

Related Articles

MGI Pharma, MethylGene Begin Phase II Trial Of MG98.

September 28, 2001

The Clinical Cancer Letter To End Print Edition In 2010

November 27, 2009

Combined analysis moves Herceptin to adjuvant setting in breast cancer.

May 27, 2005

Paul Marks To Retire As President, CEO Of Memorial Sloan-Kettering Cancer Center

December 11, 1998

ACS Ask Stronger Federal Action Against Cigarettes

November 23, 1979

MSK Withdraws Form Breast Cancer Nutrition Study Over Chemotherapy Issue; Program Still “Going Well”

June 21, 1985